Gilead Sciences, Inc. (NASDAQ:GILD) was upgraded by Vetr from a “buy” rating to a “strong-buy” rating in a report issued on Tuesday. The brokerage currently has a $74.58 target price on the biopharmaceutical company’s stock. Vetr‘s price objective would indicate a potential upside of 12.90% from the stock’s previous close. A number of other equities […]
